OECD says further progress is needed in Hungary

20 November 2017
hungary_flag-1-

The Organization for Economic Cooperation and Development (OECD) continues to bring bad news about the health status of the Hungarian population.

The Hungarian Association of Innovative Pharmaceutical Manufacturers (AIPM) believes that the key to progress could be the steady cooperation of all actors in the health sector.

Original article stated that “the average healthcare spending per capita in the OECD countries is $4,003 – Hungary spends half of this, $2101.

The Paris-based organization published its data on November 10, focusing on the life expectancy at birth, the healthcare spending per capita, and the leading causes of death, wrote the online news magazine, hvg.hu. In Spain, life expectancy at birth increased to 83 years, getting them second place behind Japan (83.9 years) among the countries examined. The OECD average is 80.6 years; in Hungary, this number is 75.7 years. Only Mexico, Brazil, Latvia, Lithuania, Columbia, Russia, Indonesia, India and South Africa are behind us on the list, with the African country presenting a life expectancy at birth of only 57.4 years.

The research examined the amounts of the healthcare spending per capita (in US $ looking at the year 2016); the USA leads the way (with $9,892/person/year), the OECD average is $4,003, and Hungary spends half of this, $2,101, which is about 562,000 forints.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical